Cargando…

Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()

INTRODUCTION: A combination of antihistamines and oral corticosteroids is often used to treat acute symptoms of allergic rhinitis. OBJECTIVE: To evaluate safety and efficacy of desloratadine plus prednisolone in the treatment of acute symptoms of children (2–12 years) with allergic rhinitis, and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wandalsen, Gustavo F., Miranda, Carolina, Ensina, Luis Felipe, Sano, Flavio, Amazonas, Roberto Bleul, Silva, Joyce Macedo da, Solé, Dirceu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449020/
https://www.ncbi.nlm.nih.gov/pubmed/27670203
http://dx.doi.org/10.1016/j.bjorl.2016.08.009
_version_ 1784784196941643776
author Wandalsen, Gustavo F.
Miranda, Carolina
Ensina, Luis Felipe
Sano, Flavio
Amazonas, Roberto Bleul
Silva, Joyce Macedo da
Solé, Dirceu
author_facet Wandalsen, Gustavo F.
Miranda, Carolina
Ensina, Luis Felipe
Sano, Flavio
Amazonas, Roberto Bleul
Silva, Joyce Macedo da
Solé, Dirceu
author_sort Wandalsen, Gustavo F.
collection PubMed
description INTRODUCTION: A combination of antihistamines and oral corticosteroids is often used to treat acute symptoms of allergic rhinitis. OBJECTIVE: To evaluate safety and efficacy of desloratadine plus prednisolone in the treatment of acute symptoms of children (2–12 years) with allergic rhinitis, and to compare it to dexchlorpheniramine plus betamethasone. METHODS: Children with moderate/severe persistent allergic rhinitis and symptomatic (nasal symptoms score [0–12] ≥ 6) were allocated in a double-blind, randomized fashion to receive dexchlorpheniramine plus betamethasone (n = 105; three daily doses) or desloratadine plus prednisolone (n = 105; single dose followed by two of placebo) for 7 days. At the beginning and end of the evaluation, the following were obtained: nasal symptoms score, extra nasal symptoms score, peak nasal inspiratory flow, blood biochemistry, and electrocardiogram. Ninety-six children of the dexchlorpheniramine plus betamethasone group and 98 of the desloratadine plus prednisolone group completed the protocol. RESULTS: The two groups were similar regarding initial and final nasal symptoms scores, extra nasal symptoms scores and peak nasal inspiratory flow. A drop of 76.4% and 79.1% for nasal symptoms score, 86.0% and 79.2% for extra nasal symptoms score, as well as an increase of 25.2% and 24.3% for peak nasal inspiratory flow occurred for those treated with desloratadine plus prednisolone and dexchlorpheniramine plus betamethasone, respectively. There were no significant changes in blood chemistry. Sinus tachycardia was the most frequent electrocardiogram change, but with no clinical significance. Drowsiness was reported significantly more often among those of dexchlorpheniramine plus betamethasone group (17.14% × 8.57%, respectively). CONCLUSION: The desloratadine plus prednisolone combination was able to effectively control acute symptoms of rhinitis in children, improving symptoms and nasal function. Compared to the dexchlorpheniramine plus betamethasone combination, it showed similar clinical action, but with a lower incidence of adverse events and higher dosing convenience.
format Online
Article
Text
id pubmed-9449020
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94490202022-09-09 Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial() Wandalsen, Gustavo F. Miranda, Carolina Ensina, Luis Felipe Sano, Flavio Amazonas, Roberto Bleul Silva, Joyce Macedo da Solé, Dirceu Braz J Otorhinolaryngol Original Article INTRODUCTION: A combination of antihistamines and oral corticosteroids is often used to treat acute symptoms of allergic rhinitis. OBJECTIVE: To evaluate safety and efficacy of desloratadine plus prednisolone in the treatment of acute symptoms of children (2–12 years) with allergic rhinitis, and to compare it to dexchlorpheniramine plus betamethasone. METHODS: Children with moderate/severe persistent allergic rhinitis and symptomatic (nasal symptoms score [0–12] ≥ 6) were allocated in a double-blind, randomized fashion to receive dexchlorpheniramine plus betamethasone (n = 105; three daily doses) or desloratadine plus prednisolone (n = 105; single dose followed by two of placebo) for 7 days. At the beginning and end of the evaluation, the following were obtained: nasal symptoms score, extra nasal symptoms score, peak nasal inspiratory flow, blood biochemistry, and electrocardiogram. Ninety-six children of the dexchlorpheniramine plus betamethasone group and 98 of the desloratadine plus prednisolone group completed the protocol. RESULTS: The two groups were similar regarding initial and final nasal symptoms scores, extra nasal symptoms scores and peak nasal inspiratory flow. A drop of 76.4% and 79.1% for nasal symptoms score, 86.0% and 79.2% for extra nasal symptoms score, as well as an increase of 25.2% and 24.3% for peak nasal inspiratory flow occurred for those treated with desloratadine plus prednisolone and dexchlorpheniramine plus betamethasone, respectively. There were no significant changes in blood chemistry. Sinus tachycardia was the most frequent electrocardiogram change, but with no clinical significance. Drowsiness was reported significantly more often among those of dexchlorpheniramine plus betamethasone group (17.14% × 8.57%, respectively). CONCLUSION: The desloratadine plus prednisolone combination was able to effectively control acute symptoms of rhinitis in children, improving symptoms and nasal function. Compared to the dexchlorpheniramine plus betamethasone combination, it showed similar clinical action, but with a lower incidence of adverse events and higher dosing convenience. Elsevier 2016-09-13 /pmc/articles/PMC9449020/ /pubmed/27670203 http://dx.doi.org/10.1016/j.bjorl.2016.08.009 Text en © 2016 Published by Elsevier Editora Ltda. on behalf of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Wandalsen, Gustavo F.
Miranda, Carolina
Ensina, Luis Felipe
Sano, Flavio
Amazonas, Roberto Bleul
Silva, Joyce Macedo da
Solé, Dirceu
Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()
title Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()
title_full Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()
title_fullStr Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()
title_full_unstemmed Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()
title_short Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()
title_sort association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449020/
https://www.ncbi.nlm.nih.gov/pubmed/27670203
http://dx.doi.org/10.1016/j.bjorl.2016.08.009
work_keys_str_mv AT wandalsengustavof associationbetweendesloratadineandprednisoloneinthetreatmentofchildrenwithacutesymptomsofallergicrhinitisadoubleblindrandomizedandcontrolledclinicaltrial
AT mirandacarolina associationbetweendesloratadineandprednisoloneinthetreatmentofchildrenwithacutesymptomsofallergicrhinitisadoubleblindrandomizedandcontrolledclinicaltrial
AT ensinaluisfelipe associationbetweendesloratadineandprednisoloneinthetreatmentofchildrenwithacutesymptomsofallergicrhinitisadoubleblindrandomizedandcontrolledclinicaltrial
AT sanoflavio associationbetweendesloratadineandprednisoloneinthetreatmentofchildrenwithacutesymptomsofallergicrhinitisadoubleblindrandomizedandcontrolledclinicaltrial
AT amazonasrobertobleul associationbetweendesloratadineandprednisoloneinthetreatmentofchildrenwithacutesymptomsofallergicrhinitisadoubleblindrandomizedandcontrolledclinicaltrial
AT silvajoycemacedoda associationbetweendesloratadineandprednisoloneinthetreatmentofchildrenwithacutesymptomsofallergicrhinitisadoubleblindrandomizedandcontrolledclinicaltrial
AT soledirceu associationbetweendesloratadineandprednisoloneinthetreatmentofchildrenwithacutesymptomsofallergicrhinitisadoubleblindrandomizedandcontrolledclinicaltrial